Freshdi Logo
Freshdi Logo

Order Skyrizi (risankizumab) - Image 1
Order Skyrizi (risankizumab) - Image 1

Order Skyrizi (risankizumab)

|

11 views


Negotiable

In stock

Minimum order quantity: 10 Box

Open to price negotiation

Supplier Country: France

Export market: Australia, Austria, Aruba, Armenia, Argentina


Key Takeaways

Freshdi AI is analyzing this product...

Subcutaneous Injection Delivery
IL-23 Targeted Therapy
Once Every 8 Weeks Dosing

Product Specifications

Minimum Order Quantity:

10 Box

Trade Term:

CIF

Port Of Loading:

Guangzhou, China, Cn (GZH/CAN)

Indication:

Moderate To Severe Plaque Psoriasis, Psoriatic Arthritis, And Ulcerative Colitis

Payment Term:

Money Gram, T/T, W/U

Dosage Frequency:

Once Every 8 Weeks

Material:

Other

Packaging Properties:

Reusable Packaging, Single-Use Packaging

Clinical Efficacy:

Significant Improvement In Skin Lesions, Joint Pain, And Gastrointestinal Symptoms

Route Of Administration:

Subcutaneous Injection

Therapeutic Approach:

Targeted Immune Modulation

Mechanism Of Action:

Targets Interleukin-23 (il-23) To Reduce Inflammation

4.6

France FlagFrance

Distribution / Wholesale, Exporter/Wholesaler, Food manufacturing

France

Activity signals

Inquiry Open Rate

62%

Total inquiries received

40

Inquiries Read

25

Export Markets

Based on the information provided by the supplier.

Australia FlagAustralia

Austria FlagAustria

Aruba FlagAruba

Armenia FlagArmenia

Argentina FlagArgentina

Central America & Caribbean

24%

Western Europe

24%

Oceania

22%

Eastern Europe

17%

East Africa

13%

Verification information

Verification information

Verify business documents

By Freshdi Verification System

Verify phone number

Buyer Verification Team

Verify account email

By Freshdi.com

Verify work email

External Validation

Business Registered ID

Supplier confirmed with Freshdi

Reviews of this Product

No reviews yet

Be the first to share your experience - your feedback helps other buyers trade with confidence.

Product descriptions from the supplier

Skirizi (Risankizumab)

Skirizi (Risankizumab) product image

Product Overview

Skirizi (risankizumab) is a biologic medication indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ulcerative colitis. It is a human monoclonal antibody that targets interleukin-23 (IL-23), helping to reduce inflammation and control disease symptoms.

Key Features

Skirizi is administered via subcutaneous injection and is designed to provide targeted immune modulation. It has demonstrated significant improvement in skin lesions, joint pain, and gastrointestinal symptoms in clinical studies. The treatment is typically prescribed for patients who have not responded adequately to other therapies.

Usage and Administration

Skirizi is administered once every 8 weeks. The dosage and frequency are determined by the patient’s condition and response to treatment. It is important to follow the prescribed regimen to achieve optimal outcomes.

You are viewing details for Order Skyrizi (risankizumab). The information provided here is either posted directly by the supplier, who is responsible for its accuracy, or collected by Freshdi AI from publicly available sources. Freshdi strives to make product information as useful and reliable as possible, but we do not guarantee complete accuracy. If you notice any incorrect or misleading details, please use the Report Product option so our team can review and address it quickly.

Order Skyrizi (risankizumab)

Negotiable

Min. order: Negotiable

Contact this Supplier


Orangoo

France FlagFrance

4.6

Jerome Cheval (Founder/ Owner)

Active

Business type

Distribution / Wholesale, Exporter/Wholesaler, Food manufacturing

Main Export Markets